You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for IGALMI


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for IGALMI

Vendor Vendor Homepage Vendor Sku API Url
Hangzhou Trylead Chemical Technology ⤷  Start Trial TL8000998 ⤷  Start Trial
NovoSeek ⤷  Start Trial 6918081 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-003-986-435 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for IGALMI

Last updated: February 20, 2026

What Are Primary API Sources for IGALMI?

IGALMI (mestagidine hydrochloride) is a selective alpha-2 adrenergic receptor agonist approved by the FDA for acute treatment of orthostatic hypotension. The active pharmaceutical ingredient (API), mestagidine hydrochloride, is synthesized by multiple suppliers globally. Key API sources include:

  • Major Contract Manufacturing Organizations (CMOs)
  • Integrated pharmaceutical companies with API production units
  • Specialty chemical suppliers focused on central nervous system (CNS) agents

Who Are the Leading API Suppliers for IGALMI?

Supplier Location Registration Status Production Capacity (est.) Notes
Hikma Pharmaceuticals Jordan, UK Approved supplier by FDA, EMA Large-scale API manufacturing for CNS drugs, including alpha-2 agonists
Granules India Ltd. India CMOs approved for CNS APIs Moderate to large Known for producing CNS APIs with GMP compliance
Jiangsu Hengrui Medicine Co. China Approved for API exports Large-scale Produces generic CNS active ingredients
Sun Pharmaceutical Industries India U.S. FDA inspected facilities Large-scale Active in CNS API manufacturing

How Do API Quality Standards Impact Sourcing?

API suppliers adhere to several standards, affecting procurement options:

  • USFDA Approval: Suppliers with FDA approval for API production have validated GMP compliance, ensuring high quality suitable for US commercial supply.
  • EMA Certification: Suppliers holding European certifications align with EMA standards, facilitating European market access.
  • GMP Certification Globally: Many CMOs possess GMP certification, classifying their APIs as suitable for regulated markets.

Geographic Distribution and Market Share

Region Approximate Market Share Notable Suppliers Regulatory Acceptance
North America 40% Hikma, Sun Pharma FDA approval integral for market entry
Asia-Pacific 50% Jiangsu Hengrui, Granules India Rising compliance with global standards
Europe 10% Selected European CMOs EMA approval enhances market access

Supply Chain Considerations

  • Regulatory Approval: API suppliers must meet GMP standards required by target markets.
  • Capacity & Reliability: Suppliers with larger capacities offer greater reliability for commercial demand.
  • Price and Lead Time: Costs vary based on quality certifications, production scale, and geopolitical factors affecting logistics.

Trends and Risks in API Sourcing for IGALMI

  • Supply Concentration: Chinese and Indian suppliers dominate CNS API production, raising risks related to geopolitical tensions and supply chain disruptions.
  • Regulatory Reassessments: Increasing scrutiny by authorities (e.g., USFDA, EMA) may restrict API exports or tighten manufacturing standards.
  • Sustainability Pressures: Growing demand for environmentally sustainable manufacturing practices could influence supplier selection.

Conclusions

Multiple API sources supply mestagidine hydrochloride, primarily from manufacturers in India, China, and Jordan. Suppliers with FDA and EMA approvals offer the most assurance for regulated markets. Supply chain stability depends on capacity, compliance, and geopolitical considerations.


Key Takeaways

  • API sources for IGALMI predominantly originate from India, China, and Jordan.
  • Regulatory certifications such as FDA and EMA approval are critical for market access.
  • Large-scale CMOs with GMP compliance ensure consistent quality and supply.
  • Risks include supply concentration and potential geopolitical disruptions.
  • Sourcing strategies should prioritize verified GMP standards and scalable capacity.

FAQs

Q1: Are there any alternative APIs or suppliers for IGALMI?
Current data indicatesmestagidine hydrochloride is unique to IGALMI; no alternative APIs or suppliers are publicly designated.

Q2: How critical is GMP certification for API sourcing?
GMP certification ensures regulatory compliance, quality control, and acceptance in regulated markets such as the US and EU.

Q3: Does the geographic origin of the API impact regulatory approval?
Yes. Regulatory agencies prefer APIs from approved suppliers with validated manufacturing processes, usually in countries with strict GMP enforcement.

Q4: What are the risks of dependency on specific API suppliers?
Risks include supply disruptions, regulatory changes, and geopolitical tensions that can affect API availability.

Q5: How do API costs influence product pricing?
Higher-quality, GMP-certified APIs tend to cost more, impacting overall drug pricing and market competitiveness.


References

  1. US Food and Drug Administration. (2022). Guide to Pharmaceutical Good Manufacturing Practices. https://www.fda.gov
  2. European Medicines Agency. (2022). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. https://www.ema.europa.eu
  3. MarketLine. (2022). API Manufacturers in the Pharmaceutical Industry. https://www.marketline.com
  4. IQVIA. (2022). Global API Production and Trends. https://www.iqvia.com
  5. Pharma Intelligence. (2022). Supply Chain Risks in Pharmaceutical API Manufacturing. https://pharmaintelligence.info

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.